Skip to main content

Advertisement

SpringerLink
Log in

Impact of the supplementation of melatonin on oxidative stress marker and serum endothelin-1 in patients with metabolic syndrome

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Objective

Metabolic syndrome (MetS) is characterized by the cluster of risk factors associated with diabetes and cardiovascular diseases. Given the influential role of oxidative stress (OxS) in the pathogenesis of MetS and the antioxidant properties of melatonin, our study aims to investigate the impact of melatonin supplementation on OxS biomarkers and serum endothelin-1 (ET-1) levels in patients diagnosed with MetS.

Methods

This double-blind, placebo-controlled, randomized clinical trial involved male and female adult participants with MetS. Subjects in the melatonin and control groups were administered 6 mg/day of encapsulated powdered melatonin or placebo (wheat flour), respectively, over a 12-week period. We evaluated serum levels of malondialdehyde (MDA), superoxide dismutase (SOD) activity, and ET-1 in MetS patients, both pre- and post-intervention.

Results

Melatonin supplementation significantly decreased serum ET-1 level (1.55 ± 0.24 pg/ml vs. 0.808 ± 0.18 pg/ml; p = 0.04) and MDA (1.326 ± 0.05 μM vs. 1.134 ± 0.05 μM; p = 0.021) in the melatonin group relative to baseline values. Additionally, SOD activity displayed a significant increase (23.64 ± 2.77 U/ml vs. 41.35 ± 1.22 U/ml; p = 0.0001) in the melatonin group when compared to baseline.

Conclusion

Our research indicates that 12 weeks of melatonin supplementation in MetS patients leads to a significant reduction in serum ET-1 and MDA levels, alongside an increase in SOD activity levels relative to baseline. However, further comprehensive and well-structured randomized controlled trials are essential for establishing the effects of melatonin supplementation on OxS biomarkers in diverse age demographics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Upon request we can provide the data.

References

  1. Fahed G, Aoun L, BouZerdan M, Allam S, BouZerdan M, Bouferraa Y, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cardinali DP, Vigo DE. Melatonin, mitochondria, and the metabolic syndrome. Cell Mol Life Sci. 2017;74(21):3941–54.

    Article  CAS  PubMed  Google Scholar 

  3. Amirkalali B, Fakhrzadeh H, Sharifi F, Kelishadi R, Zamani F, Asayesh H, et al. Prevalence of metabolic syndrome and its components in the Iranian adult population: a systematic review and meta-analysis. Iranian Red Crescent Med J. 2015;17(12):e24723.

    Article  Google Scholar 

  4. Monserrat-Mesquida M, Quetglas-Llabrés M, Capó X, Bouzas C, Mateos D, Pons A, et al. Metabolic syndrome is associated with oxidative stress and proinflammatory state. Antioxidants. 2020;9(3):236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sánchez-Rodríguez MA, Martínez-Cruz M, Correa-Muñoz E, Mendoza-Núñez VM. Relationship between metabolic syndrome components and oxidative stress in elderly community-dwelling Mexicans. Ann Nutr Metab. 2010;56(4):302–7.

    Article  PubMed  Google Scholar 

  6. Tipoe GL, Leung T-M, Hung M-W, Fung M-L. Green tea polyphenols as an anti-oxidant and anti-inflammatory agent for cardiovascular protection. Cardiovasc Haematol Disord-Drug Targets. 2007;7(2):135–44.

    Article  CAS  Google Scholar 

  7. Ighodaro O, Akinloye O. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): their fundamental role in the entire antioxidant defence grid. Alexandria J Med. 2018;54(4):287–93.

    Article  Google Scholar 

  8. Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014: 360438.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Dziegielewska-Gesiak S. metabolic syndrome in an aging society - role of oxidant-antioxidant imbalance and inflammation markers in disentangling atherosclerosis. Clin Interv Aging. 2021;16:1057–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Monserrat-Mesquida M, Quetglas-Llabrés M, Capó X, Bouzas C, Mateos D, Pons A, et al. Metabolic syndrome is associated with oxidative stress and proinflammatory state. Antioxidants (Basel, Switzerland). 2020;9(3):236.

    CAS  PubMed  Google Scholar 

  11. Chen X, Yan XR, Liu J, Zhang LP. Chaiqi decoction ameliorates vascular endothelial injury in metabolic syndrome by upregulating autophagy. Am J Transl Res. 2020;12(9):4902–22.

    PubMed  PubMed Central  Google Scholar 

  12. Campia U, Tesauro M, Di Daniele N, Cardillo C. The vascular endothelin system in obesity and type 2 diabetes: pathophysiology and therapeutic implications. Life Sci. 2014;118(2):149–55.

    Article  CAS  PubMed  Google Scholar 

  13. Schneider JG, Tilly N, Hierl T, Sommer U, Hamann A, Dugi K, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15(11):967–72.

    Article  CAS  PubMed  Google Scholar 

  14. Yu AP, Tam BT, Yau WY, Chan KS, Yu SS, Chung TL, et al. Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults. Diabetol Metab Syndr. 2015;7:111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Aboonabi A, Meyer RR, Singh I. The association between metabolic syndrome components and the development of atherosclerosis. J Hum Hypertens. 2019;33(12):844–55.

    Article  PubMed  Google Scholar 

  16. Xie S, Fan W, He H, Huang F. Role of melatonin in the regulation of pain. J Pain Res. 2020;13:331.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wang YQ, Jiang YJ, Zou MS, Liu J, Zhao HQ, Wang YH. Antidepressant actions of melatonin and melatonin receptor agonist: focus on pathophysiology and treatment. Behav Brain Res. 2022;420: 113724.

    Article  CAS  PubMed  Google Scholar 

  18. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol (Oxf). 2012;205(2):209–23.

    Article  CAS  PubMed  Google Scholar 

  19. Ríos-Lugo MJ, Cano P, Jiménez-Ortega V, Fernández-Mateos MP, Scacchi PA, Cardinali DP, et al. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats. J Pineal Res. 2010;49(4):342–8.

    Article  PubMed  Google Scholar 

  20. Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011;50(3):261–6.

    Article  PubMed  Google Scholar 

  21. Hacışevki A, Baba B. An overview of melatonin as an antioxidant molecule: a biochemical approach [Internet]. Melatonin - Molecular Biology, Clinical and Pharmaceutical Approaches. IntechOpen; 2018. Available from: https://doi.org/10.5772/intechopen.79421.

  22. Zare Javid A, Hosseini SA, Gholinezhad H, Moradi L, Haghighi-Zadeh MH, Bazyar H. Antioxidant and anti-inflammatory properties of melatonin in patients with type 2 diabetes mellitus with periodontal disease under non-surgical periodontal therapy: a double-blind, placebo-controlled trial. Diabetes Metab Syndr Obes: Targets Ther. 2020;13:753–61.

    Article  Google Scholar 

  23. Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr (Edinburgh, Scotland). 2019;38(1):191–6.

    Article  CAS  Google Scholar 

  24. Szewczyk-Golec K, Rajewski P, Gackowski M, Mila-Kierzenkowska C, Wesołowski R, Sutkowy P, et al. Melatonin supplementation lowers oxidative stress and regulates adipokines in obese patients on a calorie-restricted diet. Oxid Med Cell Longev. 2017;2017:8494107.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Hu ZP, Fang XL, Fang N, Wang XB, Qian HY, Cao Z, et al. Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF-κB system in high-fat-fed rabbits. J Pineal Res. 2013;55(4):388–98.

    Article  CAS  PubMed  Google Scholar 

  26. Khonakdar Tarsi A, Ansari M, Ghazi Khansari M, Keramatipour M, Ebrahimi A, Emamgholipour S, et al. Melatonin inhibits endothelin-1 and induces endothelial nitric oxide synthase genes expression throughout hepatic ischemia/reperfusion in rats. Afr J Biotechnol. 2012;11(58):12222–8.

    CAS  Google Scholar 

  27. MesriAlamdari N, Mahdavi R, Roshanravan N, LotfiYaghin N, Ostadrahimi AR, Faramarzi E. A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women. Horm Metab Res. 2015;47(7):504–8.

    CAS  Google Scholar 

  28. Jiki Z, Lecour S, Nduhirabandi F. Cardiovascular benefits of dietary melatonin: a myth or a reality? Front Physiol. 2018;9:528.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Peschke E, Bach AG, Mühlbauer E. Parallel signaling pathways of melatonin in the pancreatic beta-cell. J Pineal Res. 2006;40(2):184–91.

    Article  CAS  PubMed  Google Scholar 

  30. Goyal A, Terry PD, Superak HM, Nell-Dybdahl CL, Chowdhury R, Phillips LS, et al. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetol Metab Syndr. 2014;6:124.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Chitimus DM, Popescu MR, Voiculescu SE, Panaitescu AM, Pavel B, Zagrean L, et al. Melatonin’s impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease. Biomolecules. 2020;10(9):1211.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Srinivasan V, Ohta Y, Espino J, Pariente JA, Rodriguez AB, Mohamed M, et al. Metabolic syndrome, its pathophysiology and the role of melatonin. Recent Pat Endocr Metab Immune Drug Discov. 2013;7(1):11–25.

    Article  CAS  PubMed  Google Scholar 

  33. Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011;50(3):261–6.

    Article  PubMed  Google Scholar 

  34. Kedziora-Kornatowska K, Szewczyk-Golec K, Kozakiewicz M, Pawluk H, Czuczejko J, Kornatowski T, et al. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J Pineal Res. 2009;46(3):333–7.

    Article  CAS  PubMed  Google Scholar 

  35. Ostadmohammadi V, Soleimani A, Bahmani F, Aghadavod E, Ramezani R, Reiter RJ, et al. The effects of melatonin supplementation on parameters of mental health, glycemic control, markers of cardiometabolic risk, and oxidative stress in diabetic hemodialysis patients: a randomized, double-blind, placebo-controlled trial. J Ren Nutr. 2020;30(3):242–50.

    Article  CAS  PubMed  Google Scholar 

  36. Morvaridzadeh M, Sadeghi E, Agah S, Nachvak SM, Fazelian S, Moradi F, et al. Effect of melatonin supplementation on oxidative stress parameters: a systematic review and meta-analysis. Pharmacol Res. 2020;161: 105210.

    Article  CAS  PubMed  Google Scholar 

  37. Strycharz-Dudziak M, Kiełczykowska M, Drop B, Świątek Ł, Kliszczewska E, Musik I, et al. Total Antioxidant Status (TAS), Superoxide Dismutase (SOD), and Glutathione Peroxidase (GPx) in Oropharyngeal Cancer Associated with EBV Infection. Oxid Med Cell Longev. 2019;2019:1–15.

    Article  Google Scholar 

  38. Yu A, Tam B, Yau W, Chan K, Yu S, Chung T, et al. Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults. Diabetol Metab Syndr. 2015;7(1):1–13.

    Article  Google Scholar 

  39. Tao J, Lv J, Li W, Zhang P, Mao C, Xu Z. Exogenous melatonin reduced blood pressure in late-term ovine fetus via MT1/MT2 receptor pathways. Reprod Biol. 2016;16(3):212–7.

    Article  PubMed  Google Scholar 

  40. Wang Z, Ni L, Wang J, Lu C, Ren M, Han W, et al. The protective effect of melatonin on smoke-induced vascular injury in rats and humans: a randomized controlled trial. J Pineal Res. 2016;60(2):217–27.

    Article  CAS  PubMed  Google Scholar 

  41. León J, Casado J, Jiménez Ruiz SM, Zurita MS, González-Puga C, Rejón JD, et al. Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-κβ. J Pineal Res. 2014;56(4):415–26.

    Article  PubMed  Google Scholar 

  42. Mut-Salud N, Álvarez PJ, Garrido JM, Carrasco E, Aránega A, Rodríguez-Serrano F. Antioxidant intake and antitumor therapy: toward nutritional recommendations for optimal results. Oxid Med Cell Longev. 2016;2016:6719534.

    Article  PubMed  Google Scholar 

  43. Kurutas EB. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state. Nutr J. 2015;15(1):1–22.

    Article  Google Scholar 

  44. Andersen LP, Gögenur I, Rosenberg J, Reiter RJ. The safety of melatonin in humans. Clin Drug Investig. 2016;36(3):169–75.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was financially supported by a grant No: HLRC-9612 from Ahvaz jundishapur University of Medical Sciences.

Author information

Authors and Affiliations

  1. Hyperlipidemia Research Center, Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Hossein Ghaderi-Zefrehi, Reyhaneh Niayesh‐Mehr, Zahra Niknam & Hossein Babaahmadi‐Rezaei

  2. Department of Science, Shoushtar School of Medical Sciences, Shushtar, Iran

    Faezeh Seif

  3. Department of Clinical Biochemistry, Abadan School of Medical Sciences, Abadan, Iran

    Saleh Ayashi

  4. Nutrition and Metabolic Disease Research Center, Department of Nutritional Sciences, Faculty of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Sima Jafarirad

  5. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

    Mohammad Hessam Rafiee

Authors
  1. Hossein Ghaderi-Zefrehi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faezeh Seif
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reyhaneh Niayesh‐Mehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saleh Ayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sima Jafarirad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zahra Niknam
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohammad Hessam Rafiee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hossein Babaahmadi‐Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept and Design: FS, RN-M.

Data Acquisition:SJ, ZN.

Data Analysis: SA.

Drafting the Manuscript: HG-Z, MHR, FS, RN-M.

Critical Revising of the Manuscript: HB-R, HG-Z.

Final Approval of the Manuscript: HB-R.

Corresponding author

Correspondence to Hossein Babaahmadi‐Rezaei.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical clearance

Subjects aged 18 and above who met the criteria of the National Diabetes Association for the diagnosis of metabolic syndrome were eligible to participate. Informed written consent was obtained from all study subjects.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghaderi-Zefrehi, H., Seif, F., Niayesh‐Mehr, R. et al. Impact of the supplementation of melatonin on oxidative stress marker and serum endothelin-1 in patients with metabolic syndrome. Int J Diabetes Dev Ctries (2023). https://doi.org/10.1007/s13410-023-01266-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13410-023-01266-5

Keywords

Search

Navigation